An Approval, A Chance

Context: WHO granting emergency-use licence (EUL) to India’s homegrown jab, Covaxin could enable the world to step up its fight against Corona virus.

Significance of granting Emergency-Use Licence (EUL) for Covaxin

• Aatmanirbhar opportunity: EUL to India’s homegrown jab, Covaxin could enable the world to step up its fight against the virus if Bharat Biotech is able to improve its production capacity.
• Safety first: As Covaxin uses a disabled virus to trigger an immune response, it is considered a safe approach and provides dependable defence against virus.
• Inactivated pathogen cannot replicate in human cells but triggers a broad-scale immune response involving both antibodies and T cells.
• Pave way for widespread distribution across the globe and remove uncertainties regarding travel abroad by Covaxin recipients.
• Brightened prospects for children’s vaccine: Though, it will be subject to different regulatory procedures.
• Recently, the Indian government recommended EUA for Covaxin in the age group of 2-18 years, implies that, India is a step away from clearing the use of the vaccine for children.

Conclusion: The Hyderabad-based company, Bharat Biotech has an opportunity, and responsibility, to position Indian scientific research at the core of this endeavour.

==========================================================================================